摘要
The current management therapies for hepatocellular carcinoma(HCC) patients are discussed in this review. Despite the development of new therapies, HCC remains a "difficult to treat" cancer because HCC typically occurs in advanced liver disease or hepatic cirrhosis. The progression of multistep and multicentric HCC hampers the prevention of the recurrence of HCC. Many HCC patients are treated with surgical resection and radiofrequency ablation(RFA), although these modalities should be considered in only selected cases with a certain HCC number and size. Although there is a shortage of grafts, liver transplantation has the highest survival rates for HCC. Several modalities are salvage treatments; however, intensive care in combination with other modalities or in combination with surgical resection or RFA might offer a better prognosis. Sorafenib is useful for patients with advanced HCC. In the near future, HCC treatment will include stronger molecular targeted drugs, which will have greater potency and fewer adverse events. Further studies will be ongoing.
The current management therapies for hepatocellularcarcinoma （HCC） patients are discussed in this review.Despite the development of new therapies, HCCremains a ＂difficult to treat＂ cancer because HCCtypically occurs in advanced liver disease or hepaticcirrhosis. The progression of multistep and multicentricHCC hampers the prevention of the recurrence of HCC.Many HCC patients are treated with surgical resectionand radiofrequencyablation （RFA）, although thesemodalities should be considered in only selected caseswith a certain HCC number and size. Although there is ashortage of grafts, liver transplantation has the highestsurvival rates for HCC. Several modalities are salvagetreatments; however, intensive care in combinationwith other modalities or in combination with surgicalresection or RFA might offer a better prognosis. Sorafenibis useful for patients with advanced HCC. In the nearfuture, HCC treatment will include stronger moleculartargeted drugs, which will have greater potency andfewer adverse events. Further studies will be ongoing.
